ST
Insider
Sergio Traversa
Chief Executive OfficerSergio Traversa (Chief Executive Officer) filed 3 Form 4 reports in the trailing twelve months (3 purchases, 0 sales), most often in Relmada Therapeutics, Inc. (RLMD). Across 2 priced purchase filings, the average 21-session return was +25.0% from execution and +18.3% from disclosure (delay-adjusted; derived). The largest single filing was $828K of RLMD (200,000 sh across 2 lots, as filed), executed Sep 9.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+25.0%
avg across 2 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+18.3%
same 2 filings, from disclosure
Filings, ttm
3
3 buys · 0 sells
Median delay
1d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$1.5M
shares × price, as filed
Last traded
Sep 10
Filed Sep 11
Median ADV $7.1M across their filed names
33% of their measured filings could not be priced (delisted or unquoted names). The returns above cover only what still trades.
Open performance→Volume by month
Buys $1.5M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
3 filings
Sector per market data · by filing · past 12 months
Most traded names
RLMDRecent filings
RLMDPURCHASE
Relmada Therapeutics, Inc.
View filing →
$828K200,000 sh across 2 lots
Exec Sep 9
Filed Sep 11 · 7:30 AM ET RLMDPURCHASE Relmada Therapeutics, Inc. View filing → $113K
27,500 sh × $4.12
Exec Dec 15 2025
Filed Dec 16 2025 · 9:30 AM ET RLMDPURCHASE Relmada Therapeutics, Inc. View filing → $600K
272,500 sh × $2.20
Exec Nov 5 2025
Filed Nov 6 2025 · 7:30 AM ET RLMDPURCHASE Relmada Therapeutics, Inc. View filing → $304K
106,986 sh across 2 lots
Exec Sep 9 2024
Filed Sep 11 2024 · 5:30 PM ET